<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00756665</url>
  </required_header>
  <id_info>
    <org_study_id>33567</org_study_id>
    <nct_id>NCT00756665</nct_id>
  </id_info>
  <brief_title>Prostate Active Surveillance Study</brief_title>
  <acronym>PASS</acronym>
  <official_title>Canary Prostate Active Surveillance Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canary Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Early Detection Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Prostate Active Surveillance Study (PASS) is a research study for men who have chosen
      active surveillance as a management plan for their prostate cancer. Active surveillance is
      defined as close monitoring of prostate cancer with the offer of treatment if there are
      changes in test results. This study seeks to discover markers that will identify cancers that
      are more aggressive from those tumors that grow slowly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, prospective active surveillance study with selective intervention in
      patients with previously untreated, clinically localized prostate cancer at diagnosis.
      Candidates are assessed based on an extended core biopsy, serum PSA (including PSA kinetics,
      if available), digital rectal examination (DRE), and assessment of cancer grade and extent.

      Active surveillance is defined as serial PSA measurements and prostate examination with
      routine prostate biopsy and therapeutic intervention considered at the time one or more of
      the following:

        -  Grade or volume progression

        -  Clinical progression

      The objectives of the study are as follows:

      Primary Objective

      • To discover and confirm biomarkers that predict aggressive disease as defined by
      pre-specified histological, PSA, clinical criteria, or outcomes based on these variables.

      Secondary Objectives

        -  To determine the proportion of patients on active surveillance who progress based on the
           above criteria.

        -  To determine the clinical predictors of disease progression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">2300</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, plasma, white cells, DNA, urine, prostate tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Urology Clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the prostate.

          -  Clinically localized prostate cancer: T1-2, NX or N0, MX or M0.

          -  No previous treatment for prostate cancer (including hormonal therapy, radiation
             therapy, surgery, or chemotherapy).

          -  ECOG Performance Status 0 or 1.

          -  Patient has elected Active Surveillance as preferred management plan for prostate
             cancer.

          -  Patient consent has been obtained according to local Institutional Review Board for
             acquisition of research specimens.

          -  Patient is accessible and compliant for follow-up.

          -  Prostate biopsy requirements:

               1. If diagnosis was within one year of baseline visit, participant must have at
                  least one biopsy with at least 10 cores.

               2. If diagnosis was more than 1 year prior to baseline visit, participant must have
                  a minimum of 2 biopsies, one of which must be within 2 years prior to baseline
                  visit.

        Exclusion Criteria:

          -  Unwillingness or inability to undergo serial prostate biopsy.

          -  History of other malignancies, except: adequately treated non-melanoma skin cancer or
             adequately treated superficial bladder cancer (Ta) or other solid tumors curatively
             treated with no evidence of disease for &gt; 5 years.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel W. Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James D. Brooks, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin E. Gleave, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ian M. Thompson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health Science Center, San Antonio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter R. Carroll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael D. Fabrizio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Virginia Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew A Wagner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center/Harvard Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Todd M. Morgan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lisa F Newcomb, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher P Filson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Newcomb, PhD</last_name>
    <email>lnewcomb@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imelda Tenggara-Hunter</last_name>
      <phone>415-353-7348</phone>
      <email>itenggara@urology.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Peter R. Carroll, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Ferrari, RN</last_name>
      <phone>650-725-5543</phone>
      <email>mferrari@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>James D. Brooks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Almira Catic</last_name>
      <phone>404-778-7397</phone>
      <email>acatic@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher P Filson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center/Harvard Medical School</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catrina Crociani</last_name>
      <phone>617-667-2898</phone>
      <email>ccrocian@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew A. Wagner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Das</last_name>
      <phone>248-252-5611</phone>
      <email>sanjaykd@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Todd M. Morgan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center, San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Mullis, CCRP</last_name>
      <phone>210-450-0705</phone>
      <email>mullish@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Ian M. Thompson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael A. Liss, MD, MAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical School</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leigh Ann Brand, CCRP</last_name>
      <phone>757-452-3464</phone>
      <email>lbrand@urologyofva.net</email>
    </contact>
    <investigator>
      <last_name>Michael D. Fabrizio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Branda Levchak</last_name>
      <phone>206-277-4760</phone>
      <email>Branda.Levchak@va.gov</email>
    </contact>
    <investigator>
      <last_name>Daniel W. Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chenee Holcomb</last_name>
      <phone>206-598-0850</phone>
      <email>cnh3@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel W. Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Ma</last_name>
      <phone>604-875-4111</phone>
      <phone_ext>66557</phone_ext>
      <email>jonathan.ma@vch.ca</email>
    </contact>
    <investigator>
      <last_name>Martin E. Gleave, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Warlick CA, Allaf ME, Carter HB. Expectant treatment with curative intent in the prostate-specific antigen era: triggers for definitive therapy. Urol Oncol. 2006 Jan-Feb;24(1):51-7. Review.</citation>
    <PMID>16414495</PMID>
  </reference>
  <reference>
    <citation>Carter HB, Walsh PC, Landis P, Epstein JI. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol. 2002 Mar;167(3):1231-4.</citation>
    <PMID>11832703</PMID>
  </reference>
  <reference>
    <citation>Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R, Dearnaley D. Early outcomes of active surveillance for localized prostate cancer. BJU Int. 2005 May;95(7):956-60.</citation>
    <PMID>15839912</PMID>
  </reference>
  <reference>
    <citation>Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol. 2006 Jan-Feb;24(1):46-50.</citation>
    <PMID>16414494</PMID>
  </reference>
  <reference>
    <citation>Meng MV, Elkin EP, Harlan SR, Mehta SS, Lubeck DP, Carroll PR. Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE. J Urol. 2003 Dec;170(6 Pt 1):2279-83.</citation>
    <PMID>14634396</PMID>
  </reference>
  <reference>
    <citation>Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol. 2004 Apr;171(4):1520-4.</citation>
    <PMID>15017211</PMID>
  </reference>
  <reference>
    <citation>Roemeling S, Roobol MJ, de Vries SH, Wolters T, Gosselaar C, van Leenders GJ, Schröder FH. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol. 2007 May;51(5):1244-50; discussion 1251. Epub 2006 Dec 5.</citation>
    <PMID>17161520</PMID>
  </reference>
  <reference>
    <citation>Kattan MW, Eastham JA, Wheeler TM, Maru N, Scardino PT, Erbersdobler A, Graefen M, Huland H, Koh H, Shariat S, Slawin KM, Ohori M. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol. 2003 Nov;170(5):1792-7.</citation>
    <PMID>14532778</PMID>
  </reference>
  <reference>
    <citation>Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schröder FH. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol. 2007 Jan;177(1):107-12; discussion 112.</citation>
    <PMID>17162015</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2008</study_first_submitted>
  <study_first_submitted_qc>September 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2008</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Daniel Lin</investigator_full_name>
    <investigator_title>Professor, Urology</investigator_title>
  </responsible_party>
  <keyword>prostate</keyword>
  <keyword>cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

